{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:35:55Z","timestamp":1764570955462},"reference-count":0,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JADPRO"],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:p>The B-cell receptor signaling pathway plays an integral role in the proliferation and survival of malignant B cells. Targeting the B-cell receptor pathway via the inhibition of Bruton tyrosine kinase (BTK) has evolved the treatment of a variety of B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstr\u00f6m macroglobulinemia. Currently, there are three BTK inhibitors approved by the U.S. Food and Drug Administration: ibrutinib, acalabrutinib, and zanubrutinib. This article reviews the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions, and implications for advanced practitioners of BTK inhibitors in the treatment of B-cell malignancies.<\/jats:p>","DOI":"10.6004\/jadpro.2021.12.4.8","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T20:56:55Z","timestamp":1621976215000},"source":"Crossref","is-referenced-by-count":2,"title":["A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies"],"prefix":"10.6004","volume":"12","author":[{"given":"Donald","family":"C. Moore, PharmD, BCPS, BCOP, DPLA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Thompson, PharmD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","published-online":{"date-parts":[[2021,5,1]]},"container-title":["Journal of the Advanced Practitioner in Oncology"],"original-title":[],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T20:57:06Z","timestamp":1621976226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.advancedpractitioner.com\/issues\/volume-12,-number-4-(mayjun-2021)\/a-review-of-the-bruton-tyrosine-kinase-inhibitors-in-b-cell-malignancies.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5,1]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.6004\/jadpro.2021.12.4.8","relation":{},"ISSN":["2150-0878"],"issn-type":[{"value":"2150-0878","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}